LOW-PV interim analysis: Ropeginterferon versus phlebotomy in low-risk polycythemia vera

Prof Tiziano Barbui speaks to ecancer in an online interview for the virtual EHA 2020 meeting. He outlines the background, design and results of this phase II randomised trial (LOW-PV), which is comparing ropeginterferon versus phlebotomy in low-risk patients with…

LOW-PV interim analysis: Ropeginterferon versus phlebotomy in low-risk polycythemia vera

Source

0
(0)

Prof Tiziano Barbui speaks to ecancer in an online interview for the virtual EHA 2020 meeting.

He outlines the background, design and results of this phase II randomised trial (LOW-PV), which is comparing ropeginterferon versus phlebotomy in low-risk patients with polycythemia vera.

Prof Barbui concludes that ropeginterferon is safe and effective in the haematocrit on target in low-risk patients with polycythemia vera.

Sign up to ecancer for free to receive tailored email alerts for more videos like this.
ecancer.org/account/register.php

0 / 5. 0

Leave a Reply

Your email address will not be published. Required fields are marked *